Navamedic ASA launches Modifast in Norway
Oslo, 30 January 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has launched Modifast, a range of low calorie diet (LCD) meal replacement products, in the Norwegian market. Modifast is part of Navamedic’s growing portfolio of products and solutions aimed at tackling obesity and consists of supplements, prescription medications, diet replacements and online patient support portals.
“The experience from Sweden shows that Modifast and obesity related products are highly suited for online pharmacy sales. The products require significant shelf space, and we want to provide our consumers with a wide range of flavors and types of foods. This has supported the decision to launch the product range in Norway, available to order online,” said Kathrine Gamborg, CEO of Navamedic ASA.
Obesity is an increasingly growing public health challenge, and according to the World Health Organization (WHO), obesity has nearly tripled since 1975. Between 15% and 20% of people in the Nordic population are considered obese, and as a consequence, the cost of treatment and related complications are increasing. Weight loss through lifestyle intervention remains a key treatment option in the management of obesity and is often a prerequisite for patients seeking to undergo bariatric surgery.
Low calorie diets are full diet replacement products, providing 800-1200 calories per day if all regular food is replaced. Modifast is considered a low calorie diet (LCD) and is made up of drinks, soups, puddings and pasta dishes, which have all been developed to contain necessary nutrients. As of January, the Modifast product range will be available to order online via Farmasiet.no (Farmasiet), Norway’s largest online pharmacy.
“Obesity is a complex disease that, if left untreated, increases the likelihood of other diseases and conditions such as type 2 diabetes and cardiovascular disease. At Navamedic, we are excited to be able to introduce Norwegian patients to a range of LCD products that can safely support their weight loss journey and improve quality of life,” said Jennie Brogårdh, Dietitian at Navamedic ASA.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic ASA
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
About Modifast
Modifast is product range consisting of Low Calorie Diet (LCD) meal replacement products. It is designed to replace all other foods for a limited time period during weight loss or weight control, without depriving the body of the nutrients it needs. Modifast cost substitute contains between 800 and 1200 kcal per day.
Modifast has a wide range of products for weight loss, weight control and well-being. Modifast has been on the market in Europe since 1995 and is recommended by obesity clinics. How Modifast can help you depends on what your weight goal is. Different products and approaches work well in different situations. Read more on www.modifast.no
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.